• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Ainos Inc.

    9/5/25 4:10:38 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    424B5 1 form424b5.htm 424B5

     

    Filed pursuant to Rule 424(b)(5)

    Registration No. 333-279880

     

    PROSPECTUS SUPPLEMENT

    (To Prospectus Dated June 11, 2024 and the Prospectus Supplement dated July 11, 2024)

     

     

    AINOS, INC.

     

    Up to $874,496

    of Common Stock

     

    This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated July 11, 2024, and its accompanying prospectus dated June 11, 2024 (collectively, the “Prospectus”), relating to the offer and sale of our common stock, par value $0.01 per share (the “Common Stock”) through H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, in “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, pursuant to the At the Market Offering Agreement with Wainwright dated as of May 31, 2024 (the “Sales Agreement”).

     

    We have sold $1,840,337 of securities pursuant to the Sales Agreement.

     

    As of September 5, 2025, the aggregate market value of our outstanding Common Stock held by non-affiliates, or public float calculated for purposes of General Instruction I.B.6 of Form S-3, was approximately $8,144,499, based on 4,759,021 shares of outstanding Common Stock as of September 5, 2025, of which 2,777,391 shares were held by affiliates, and a price of $4.11 per share, which was the price at which our Common Stock was last sold on the Nasdaq Capital Market on August 26, 2025.

     

    We have sold $1,840,337 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement.

     

    We are filing this prospectus supplement to amend the Prospectus to update the amount of shares we are eligible to sell pursuant to such prospectus. We are increasing the amount of shares of Common Stock we may offer and sell under the Sales Agreement to an aggregate offering price of up to $874,496 from time to time through Wainwright. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month calendar period so long as our public float remains below $75.0 million.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is accurate or complete. Any representation to the contrary is a criminal offense.

     

    H.C. Wainwright & Co.

     

    The date of this prospectus supplement is September 5, 2025

     

     

     

    Get the next $AIMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Taiwan Carbon Nano Technology Corp sold $9,425 worth of shares (2,706 units at $3.48), decreasing direct ownership by 0.26% to 1,046,206 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    10/2/25 4:10:39 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Taiwan Carbon Nano Technology Corp decreased direct ownership by 0.83% to 1,048,912 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    8/7/25 4:15:16 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Taiwan Carbon Nano Technology Corp increased direct ownership by 0.00% to 1,080,103 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    7/21/25 4:15:05 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ase Test, Inc. bought 29,476 shares (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    6/25/25 6:03:05 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

    Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

    1/21/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

    SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

    1/17/25 9:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

    Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

    1/13/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    SEC Filings

    View All

    SEC Form DEF 14A filed by Ainos Inc.

    DEF 14A - Ainos, Inc. (0001014763) (Filer)

    10/1/25 4:26:19 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ainos, Inc. (0001014763) (Filer)

    9/8/25 9:00:25 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Ainos Inc.

    424B5 - Ainos, Inc. (0001014763) (Filer)

    9/5/25 4:10:38 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Leadership Updates

    Live Leadership Updates

    View All

    Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

    Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

    1/13/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Financials

    Live finance-specific insights

    View All

    Ainos Reports Third Quarter 2024 Financial Results

    Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

    11/6/24 4:30:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Reports Second Quarter 2024 Financial Results

    Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

    8/5/24 4:15:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Reports First Quarter 2024 Financial Results

    Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

    5/13/24 4:10:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Ainos Inc.

    SC 13D - Ainos, Inc. (0001014763) (Subject)

    8/21/24 8:22:28 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    8/20/24 4:05:21 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care